A Phase 3 interventional study of Placebo and Pregabalin in Pain, Perioperative, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 7 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing pregabalin in Pain — 4 open to participants now, 4 under way, none of them phase 3. Pregabalin · Pain.
Among the 55 studies testing pregabalin in Pain, this one is the 26th largest by enrollment, is one of 4 that started in 2009, is one of 15 in phase 3, and was the 18th registered.
10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →4 of the 55 studies testing pregabalin in Pain are open now, in 1 country. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–65
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 17 · Phase 4 14
First in 2001; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is close to the median of 66 across 8,511 interventional studies indexed under Pain.
Median enrollment 64 across the 55 interventional studies. Of the 47 that completed or were terminated, 18 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
22 studies in Pain by Viatris Inc.: none open now, none under way, none of them phase 3. Of 22 finished, 18 (82%) have results posted.
Among the 22 studies in Pain by Viatris Inc., this one is the 14th largest by enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2009, is one of 10 in phase 3, and was the 8th registered.
Viatris Inc.’s Pain studies by the year they started, since 2006.
3 of the studies testing pregabalin in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186751Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07208357Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07171320Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 55 studies testing pregabalin in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 22 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is the investigate if pregabalin started a day before surgery and continued for 14 days post-operatively can reduce post-operative pain, relieve pre- and post-operative anxiety and sleep disturbances.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo as an adjunct to standard of care
Drug: Placebo
Pregabalin as an adjunct to standard of care
Drug: Pregabalin
Placebo as an adjunct to standard of care
75 mg BD for 14 days
Mean Pain on Movement Score
Mean pain on movement score was defined as the mean of the pain on movement score over Days 1 to 5 post-surgery. Pain experienced by participant during passive flexion through 90 degree and passive abduction through 30 degree at operated hip joint was evaluated on a scale of 0 to 10 where, 0= no pain and 10= worst possible pain.
Time frame: Every 12 hours from Day 1 to Day 5 post-surgery
Mean Daily Pain Score
Mean daily pain score was defined as the mean of daily pain score over Days 1 to 7 and Days 8 to 14 post-surgery. Daily Pain Rating Scale (DPRS): participant rated 11-point Likert scale ranging from 0 (no pain) to 10 (worst possible pain) during past 24-hour period. Higher score indicates greater level of pain.
Time frame: Day 1 to Day 7, Day 8 to Day 14 post-surgery
Mean Daily Sleep Interference Score
Mean daily sleep interference score was defined as the mean of daily sleep interference numeric rating scale (NRS) score over Days 1 to 5 post-surgery. Daily Sleep Interference Scale (DSIS): participant rated pain during past 24-hour period on NRS ranging from 0 (pain does not interfere with sleep) to 10 (pain completely interferes with sleep). Higher score indicates a greater level of sleep disturbance. Self-assessment performed daily on awakening prior to taking study medication.
Time frame: Day 1 to Day 5 post-surgery
Mean Anxiety Visual Analogue Scale (A-VAS)
Mean anxiety visual analogue scale (VAS) was defined as the mean of VAS score on the day of surgery and over Days 1 to 5 post-surgery. Participants measured their degree of anxiety over past 24 hours on a VAS of 0 to 100, where 0 = not at all anxious to 100 = extremely anxious.
Time frame: Day 0 to Day 5 post-surgery
Time to Mobilization After Surgery
Participant was encouraged each day (from Day 3) to attempt walking depending upon the degree of pain on standing. The first day on which the participant was able to walk for 5 steps was the day of mobilization. Median time to mobilization (in hours) was calculated till the day of mobilization.
Time frame: Day 1 to Day 5 post-surgery
Number of Participants With Rescue Medication Usage
Rescue medications were used for participants with moderate or severe resting pain. Fentanyl injection (25 microgram \[mcg\] intravenous bolus to a maximum dose of 3 milliliter/day), paracetamol tablet (15 milligram/kilogram orally to a maximum dose of 45 milligram/kilogram/day) were used as rescue medications.
Time frame: Day 0 to Day 6 post-surgery
Number of Participants With Neuropathic Pain
ID Pain questionnaire was used to assess neuropathic pain. 6 items questionnaire, did pain feel like: (1)pins and needles (2)hot/burning (3)numb (4)electrical shocks (5)is pain made worse with touch of clothing or bed sheets (6)is pain limited to your joints. "Yes" response to questions 1-5 were scored as 1, while a "yes" response to question 6 was scored as -1. "No" response were scored as 0. Overall score range -1 to 5.Higher score more indicative of pain with a neuropathic component. Number of participants with score 2 or more (which indicated nerve pain) were reported.
Time frame: Day 90, Day 180 post-surgery
| Milestone | Pregabalin | Placebo |
|---|---|---|
| Started | 35 | 37 |
| Completed | 27 | 27 |
| Not completed | 8 | 10 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Other | 5 | 6 |
Mean pain on movement score was defined as the mean of the pain on movement score over Days 1 to 5 post-surgery. Pain experienced by participant during passive flexion through 90 degree and passive abduction through 30 degree at operated hip joint was evaluated on a scale of 0 to 10 where, 0= no pain and 10= worst possible pain.
| Units on a scale | Pregabalin | Placebo |
|---|---|---|
| Mean Pain on Movement Score | 4.0 ± 0.23 | 3.9 ± 0.26 |
Mean daily pain score was defined as the mean of daily pain score over Days 1 to 7 and Days 8 to 14 post-surgery. Daily Pain Rating Scale (DPRS): participant rated 11-point Likert scale ranging from 0 (no pain) to 10 (worst possible pain) during past 24-hour period. Higher score indicates greater level of pain.
| Units on a scale | Pregabalin | Placebo |
|---|---|---|
| Days 1 to 7 (n=27,30) | 2.6 ± 0.23 | 2.6 ± 0.24 |
| Days 8 to 14 (n=26,27) | 1.8 ± 0.25 | 1.4 ± 0.25 |
Mean daily sleep interference score was defined as the mean of daily sleep interference numeric rating scale (NRS) score over Days 1 to 5 post-surgery. Daily Sleep Interference Scale (DSIS): participant rated pain during past 24-hour period on NRS ranging from 0 (pain does not interfere with sleep) to 10 (pain completely interferes with sleep). Higher score indicates a greater level of sleep disturbance. Self-assessment performed daily on awakening prior to taking study medication.
| Units on a scale | Pregabalin | Placebo |
|---|---|---|
| Mean Daily Sleep Interference Score | 2.6 ± 0.34 | 3.1 ± 0.29 |
Mean anxiety visual analogue scale (VAS) was defined as the mean of VAS score on the day of surgery and over Days 1 to 5 post-surgery. Participants measured their degree of anxiety over past 24 hours on a VAS of 0 to 100, where 0 = not at all anxious to 100 = extremely anxious.
| Units on a scale | Pregabalin | Placebo |
|---|---|---|
| Mean Anxiety Visual Analogue Scale (A-VAS) | 23.3 ± 3.33 | 24.7 ± 2.88 |
Participant was encouraged each day (from Day 3) to attempt walking depending upon the degree of pain on standing. The first day on which the participant was able to walk for 5 steps was the day of mobilization. Median time to mobilization (in hours) was calculated till the day of mobilization.
| hours | Pregabalin | Placebo |
|---|---|---|
| Time to Mobilization After Surgery | 72.500 (51.250 to 76.167) | 52.417 (46.750 to 73.250) |
Rescue medications were used for participants with moderate or severe resting pain. Fentanyl injection (25 microgram \[mcg\] intravenous bolus to a maximum dose of 3 milliliter/day), paracetamol tablet (15 milligram/kilogram orally to a maximum dose of 45 milligram/kilogram/day) were used as rescue medications.
| participants | Pregabalin | Placebo |
|---|---|---|
| Number of Participants With Rescue Medication Usage | 17 | 25 |
ID Pain questionnaire was used to assess neuropathic pain. 6 items questionnaire, did pain feel like: (1)pins and needles (2)hot/burning (3)numb (4)electrical shocks (5)is pain made worse with touch of clothing or bed sheets (6)is pain limited to your joints. "Yes" response to questions 1-5 were scored as 1, while a "yes" response to question 6 was scored as -1. "No" response were scored as 0. Overall score range -1 to 5.Higher score more indicative of pain with a neuropathic component. Number of participants with score 2 or more (which indicated nerve pain) were reported.
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | — | 2/35 (5.7%) | 23/35 (65.7%) |
| Placebo | — | 0/37 (0%) | 22/37 (59.5%) |
| Event | Pregabalin | Placebo |
|---|---|---|
| Oxygen saturation decreasedInvestigations | 1/35 | 0/37 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/35 | 0/37 |
| HypotensionVascular disorders | 1/35 | 0/37 |
| Event | Pregabalin | Placebo |
|---|---|---|
| PyrexiaGeneral disorders | 16/35 | 10/37 |
| ConstipationGastrointestinal disorders | 3/35 | 3/37 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/35 | 1/37 |
| VomitingGastrointestinal disorders | 2/35 | 3/37 |
| Haemoglobin decreasedInvestigations | 0/35 | 3/37 |
| PainGeneral disorders | 2/35 | 2/37 |
| HeadacheNervous system disorders | 2/35 | 1/37 |
| HypotensionVascular disorders | 2/35 | 2/37 |
| Back painMusculoskeletal and connective tissue disorders | 1/35 | 2/37 |
| DiarrhoeaGastrointestinal disorders | 1/35 | 1/37 |
| Age, Continuous(years) | Pregabalin | Placebo | Total |
|---|---|---|---|
| Mean | 47.1 ± 13.5 | 48.9 ± 13.3 | 48.0 ± 13.3 |
| Sex: Female, Male(Participants) | Pregabalin | Placebo | Total |
|---|---|---|---|
| Female | 15 | 20 | 35 |
| Male | 20 | 17 | 37 |
The record gives a start of Nov 2009, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →